author-photo

Jing Xu

Takeda Pharmaceutical Company

22

Papers

2399

Citations

Citation Trend

Filter By

Papers (16) Sort By

Journal Conference Others

Comparison of incidence/occurrence of cardiovascular events between ponatinib vs bosutinib among patients with at least one prior line of tyrosine kinase inhibitors in chronic myeloid leukemia in a community setting in the United States.

2021 Cancer treatment and research
Show All
- Source
- Cite
- Save
Citations (0)
An independent review of arterial occlusive events (AOEs) in the ponatinib (PON) phase II PACE trial (NCT01207440) in patients (pts) with Ph+ leukemia.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Phase 3 PhALLCON study: Ponatinib (PON) versus imatinib (IM) with reduced-intensity chemotherapy (CT) in patients (pts) with newly diagnosed Philadelphia chromosome–positive (Ph+) ALL.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1

2019 Inflammatory Bowel Diseases
Show All
- Source
- Cite
- Save
Citations (18)
The OPTIC Study: A Multicenter, Randomized, Phase 2 Trial to Evaluate Three Starting Doses of Ponatinib With Response-Based Dose Reduction in Patients with Chronic Phase Chronic Myeloid Leukemia Resistant to Prior Tyrosine Kinase Therapy

2018 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (3)
Efficacy of Vedolizumab in Fistulising Crohn’s Disease: Exploratory Analyses of Data from GEMINI 2

2018 Journal of Crohns & Colitis
Show All
- Source
- Cite
- Save
Citations (41)
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy.

2017 Inflammatory Bowel Diseases
Show All
- Source
- Cite
- Save
Citations (96)
PWE-020 Corticosteroid Dose Reduction with Vedolizumab Treatment of Crohn’s Disease

2016 Gut
Show All
- Source
- Cite
- Save
Citations (0)
PTH-072 Corticosteroid Dose Reduction in Ulcerative Colitis Patients Treated with Vedolizumab: Abstract PTH-072 Table 1

2016 Gut
Show All
- Source
- Cite
- Save
Citations (0)
Corrigendum to “Efficacy of continued vedolizumab therapy in patients with Crohn's disease who did not respond to vedolizumab induction therapy at week 6” [J Crohns Colitis 8S1 (2014) P497 S274-5]

2014 Journal of Crohns & Colitis
Show All
- Source
- Cite
- Save
Citations (6)